Aclaris Therapeutics Inc

-

Stock Issuer and Owners

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Aclaris Therapeutics Inc
TickerACRS
CIK #0001557746
CUSIP00461U105
SectorLife Sciences - Pharmaceutical Preparations
AddressSuite 400, 101 Lindenwood Drive, Malvern, PA 19355
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
Aclaris Therapeutics Inc 2024-12-04 80.0 M Exemption: 506(b) · Duration: One year or less · Commission: $4,800,000 · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001557746] 10-K
[0001557746] 10-Q
[0001557746] 3
[0001557746] 4
[0001557746] 8-K
[0001557746] D
[0001557746] SC 13D
[0001557746] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
RA Capital Management LP Aclaris Therapeutics Inc [2026-04-07] 0.0
Deep Track Capital LP Aclaris Therapeutics Inc [2026-03-17] 0.0
Vanguard Group Inc Aclaris Therapeutics Inc [2025-07-29] 0.0
BlackRock Inc Aclaris Therapeutics Inc [2025-07-17] 0.0
Millennium Management LLC Aclaris Therapeutics Inc [2025-05-05] 0.0
Adage Capital Management LP Aclaris Therapeutics Inc [2025-02-12] 0.0
Biosion Inc Aclaris Therapeutics Inc [2024-11-25] 0.5
Rock Springs Capital Management LP Aclaris Therapeutics Inc [2024-11-22] 6.32
Vivo Opportunity Fund Holdings LP Aclaris Therapeutics Inc [2024-11-21] 7.4
Millennium Management LLC Aclaris Therapeutics Inc [2024-02-14] 5.3
Vanguard Group Inc Aclaris Therapeutics Inc [2024-02-13] 6.67
BML Investment Partners LP Aclaris Therapeutics Inc [2024-01-16] 6.4
Millennium Management LLC Aclaris Therapeutics Inc [2023-12-11] 5.1
Tang Capital Partners LP Aclaris Therapeutics Inc [2023-11-24] 6.1
Citadel Advisors LLC Aclaris Therapeutics Inc [2023-09-05] 4.7
Biotechnology Value Fund L P Aclaris Therapeutics Inc [2023-03-16] 2.7
RA Capital Management LP Aclaris Therapeutics Inc [2022-04-25] 7.1
Venrock Healthcare Capital Partners II LP Aclaris Therapeutics Inc [2022-02-14] 7.5
BlackRock Inc Aclaris Therapeutics Inc [2022-02-04] 6.7
Wellington Management Group LLP Aclaris Therapeutics Inc [2022-02-04] 0.05
Biotechnology Value Fund L P Aclaris Therapeutics Inc [2022-01-24] 3.4
Foresite Capital Fund III LP Aclaris Therapeutics Inc [2020-10-27] 3.8
Rock Springs Capital Management LP Aclaris Therapeutics Inc [2020-10-26] 5.18
Adage Capital Partners GP LLC Aclaris Therapeutics Inc [2020-06-26] 5.97
Samsara Biocapital LP Aclaris Therapeutics Inc [2020-03-06] 5.2
EcoR1 Capital LLC Aclaris Therapeutics Inc [2020-02-14] 5.0
Renaissance Technologies LLC Aclaris Therapeutics Inc [2020-02-12] 6.72
MFN Partners Management LP Aclaris Therapeutics Inc [2019-10-31] 9.7
Arkin Moshe Aclaris Therapeutics Inc [2019-10-15] 8.02
Morgan Stanley Aclaris Therapeutics Inc [2019-08-29] 5.0
Rock Springs Capital Management LP Aclaris Therapeutics Inc [2019-07-29] 5.09
Man Group PLC Aclaris Therapeutics Inc [2019-07-09] 5.87
Broadfin Capital LLC Aclaris Therapeutics Inc [2019-01-29] 5.57
D E Shaw & Co LP Aclaris Therapeutics Inc [2018-11-01] 5.0
BlackRock Inc Aclaris Therapeutics Inc [2018-02-01] 7.1
Flynn James E Aclaris Therapeutics Inc [2017-10-10] 5.9
Perceptive Advisors LLC Aclaris Therapeutics Inc [2017-02-14] 5.88
Franklin Resources Inc Aclaris Therapeutics Inc [2016-02-03] 8.2
Vivo Ventures Fund VII LP Aclaris Therapeutics Inc [2015-10-20] 11.0
Sofinnova Venture Partners VIII LP Aclaris Therapeutics Inc [2015-10-16] 11.0
FMR LLC Aclaris Therapeutics Inc [2015-10-14] 0.0
RA Capital Management LLC Aclaris Therapeutics Inc [2015-10-13] 11.5
Form 3/4/5 Filer 2011 - 2026
Aclaris Therapeutics Inc
Molineaux Christopher P
Schiff Andrew N
Mehra Anand
Gowen Maxine
Humphries William D
Milano Vincent
Hall Jesse Wayne
Leonard Braden Michael
Balthaser Kevin
Walker Neal
Kolbeck Roland Wilhelm
Loerop James
Davis Hugh M
Monahan Joseph
Biosion Inc
Reasons Bryan M
Powell Andrew Kenneth William
Manion Douglas J
Cawkwell Gail
Ruffo Frank
Ali-Jackson Kamil
Tananbaum James B
Foresite Capital Management IV LLC
Foresite Capital Management III LLC
Foresite Capital Fund V LP
Foresite Capital Fund III LP
Foresite Capital Fund IV LP
Foresite Capital Management V LLC
Gordon David N
Deerfield Special Situations Fund LP
Deerfield Management Company LP
Deerfield Capital LP
Deerfield Partners LP
Flynn James E
Shanler Stuart
Fair Brett
Powala Christopher
Tullman Stephen A
FMR LLC
Bierly Rick
Vivo Ventures VII Affiliates Fund LP
Vivo Ventures Fund VII LP
Vivo Ventures VII LLC
Kolchinsky Peter
RA Capital Healthcare Fund LP
RA Capital Management LP
Cha Albert
Powell Michael
Sofinnova Management VIII LLC
Sofinnova Venture Partners VIII LP
Akkaraju Srinivas
Healy James
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Balthaser Kevin
Common Stock
2026-03-01 Option exercise 2,375
Balthaser Kevin
Restricted Stock Units · derivative
2026-03-01 Option exercise 2,375 $0.00
Balthaser Kevin
Common Stock
2026-03-01 Tax withheld 677 $2.87 1,943
Balthaser Kevin
Restricted Stock Units · derivative
2026-02-03 Option exercise 22,025 $0.00
Walker Neal
Common Stock
2026-02-03 Option exercise 63,475
Walker Neal
Common Stock
2026-02-03 Tax withheld 18,611 $3.47 64,580
Balthaser Kevin
Common Stock
2026-02-03 Tax withheld 6,449 $3.47 22,378
Loerop James
Common Stock
2026-02-03 Option exercise 20,875
Loerop James
Restricted Stock Units · derivative
2026-02-03 Option exercise 20,875 $0.00
Loerop James
Common Stock
2026-02-03 Tax withheld 5,937 $3.47 20,601
Davis Hugh M
Restricted Stock Units · derivative
2026-02-03 Option exercise 18,675 $0.00
Balthaser Kevin
Common Stock
2026-02-03 Option exercise 22,025
Davis Hugh M
Common Stock
2026-02-03 Option exercise 18,675
Walker Neal
Restricted Stock Units · derivative
2026-02-03 Option exercise 63,475 $0.00
Davis Hugh M
Restricted Stock Units · derivative
2026-02-02 Grant 96,100 $0.00
Kolbeck Roland Wilhelm
Employee Stock Option (Right to Buy) · derivative
2026-02-02 Grant 334,900 $0.00
Hall Jesse Wayne
Employee Stock Option (Right to Buy) · derivative
2026-02-02 Grant 343,300 $0.00
Loerop James
Employee Stock Option (Right to Buy) · derivative
2026-02-02 Grant 341,900 $0.00
Walker Neal
Employee Stock Option (Right to Buy) · derivative
2026-02-02 Grant 961,700 $0.00
Hall Jesse Wayne
Restricted Stock Units · derivative
2026-02-02 Grant 98,100 $0.00
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 137 109,461,163
2025-12-31 122 81,964,905
2025-09-30 103 82,884,941
2025-06-30 97 88,090,384
2025-03-31 110 89,158,573
2024-12-31 99 86,183,455
2024-09-30 82 46,958,957
2024-06-30 99 49,106,523
2024-03-31 99 53,411,192
2023-12-31 108 57,287,636
2023-09-30 145 74,325,072
2023-06-30 135 74,114,717
Form 13F Holdings
Firm Period DFND Voting Shares
Assenagon Asset Management SA [2026-06-30] SOLE 154,554 154,554
Diversified Trust Co [2026-06-30] SOLE 0 45,523
Empirical Financial Services LLC DBA Empirical Wealth Ma [2026-06-30] SOLE 15,123 16,072
Farther Finance Advisors LLC [2026-06-30] SOLE 0 1,175
Gamma Investing LLC [2026-06-30] DFND 1,020 1,020
MassMutual Private Wealth & Trust FSB [2026-06-30] SOLE 391 391
Fortitude Family Office LLC [2026-06-30] SOLE 56 56
Capital Advisors Ltd LLC [2026-06-30] SOLE 0 0
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com